PARCKA Study Endorsed for Enrollment

The Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA) and the Greater Intermountain Node (GIN) are pleased to announce that the Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs) Study has been endorsed to begin enrollment.

The primary objective of this trial is to evaluate the impact of treating opioid use disorder (OUD) in pregnant women with extended-release (XR) buprenorphine (BUP), compared to sublingual (SL) BUP, on mother and infant outcomes. This is an intent-to-treat, two-arm, open-label, pragmatic randomized controlled trial.

Site Principal Investigator Jerry Cochran, PhD, Co-Site Principal Investigator Marcela Smid, MD, Site Coordinator Jade Hill, MPH (see below), and our research team are leading MOMs here in Utah. You can learn more about MOMs here.

Jerry Cochran, PhD

Marcela Smid, MD

Jade Hill, MPH